A collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health —a health technology company dedicated to empowering physicians to do more with data—is helping to improve outcomes for Albertans living with type 2 diabetes, atherosclerotic cardiovascular disease and heart failure.
Using artificial intelligence (AI), the team has developed an analytical tool to empower patient-centric guideline optimization. The tool uses machine learning algorithms and data from electronic medical health records to support early detection and individualized treatment plans for patients, aligned with Diabetes Canada’s Clinical Practice Guidelines and the Canadian Cardiovascular Society’s Treatment Guidelines.
The novel tool is believed to be the first automated electronic data capture system validated for clinical application across Canada, providing an analysis to securely compare data against evidence-based algorithms and guidelines in the search to find opportunities to optimize care. Patients in the program meet regularly with their healthcare provider to ensure the guideline-directed therapies and decisions are being discussed. The analyses have been validated for accuracy and received Provincial Privacy Impact Assessment approval.
Work on the project is ongoing in Alberta. The collaboration demonstrates the power of AI and innovative partnerships to improve health outcomes and health system management. For more information, please contact the project lead.